Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

safety and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Used for Marketing in 2008 --, HARBIN, ... Inc. (the "Company") (OTC Bulletin Board: CKGT), a,vertically ... of cactus-based consumer products in China, today announced ... agreement with T Squared,Investments LLC (the "Investor"), whereby ...
... With employee performance module implemented in just few months, ... ... personal growth, ... of web-based employee performance and talent management software,today announced that ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing 2Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System 2
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need to sign ... key or the answer to your secret question. What,s your dog,s ... Hoyos Labs , a digital infrastructure security company, launches ... frustration that comes with usernames, passwords and PINs – 1U ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist Medical ... for its School of Medicine. Funding for this $50 million ... will be publicly launched next summer. The ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report to their ... The integration of biometrics and smart cards for ... driver,s license is one of the major trends witnessed ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... EUGENE, Ore. -- (Aug. 22, 2011) -- Seeing and exploring ... when taking in a new experience, say University of Oregon ... In experiments in the UO lab of Clifford G. Kentros, ... how neurons fire in the hippocampus of rats as they ...
... JUPITER, FL, August 22, 2011 Working closely with ... Florida campus of The Scripps Research Institute have helped identify ... damage to the genome, the entirety of an organism,s hereditary ... Nature on August 21, 2011, could not only explain ...
... The U.S. Department of Health and Human Services, Health ... post-doctoral training programs in dental public health at Case ... in oral health. Case Western Reserve University ... nearly $2.6 million. The funding will support efforts to ...
Cached Biology News:Experience puts the personal stamp on a place in memory 2Experience puts the personal stamp on a place in memory 3Scripps Research scientists help pinpoint cause of stress-related DNA damage 2CWRU School of Dental Medicine receives $2.6 million in grants 2
... Expression System with Gateway™ Technology is ... containing the polyhedrin promoter. The expression ... genome (bacmid DNA) by site-specific transposition ... The recombinant bacmid DNA is then ...
...
... Clone/PAD: ZMD.478. Immunogen: Synthetic ... of the humanmouse and bovine Math-2. ... protein. Reactivity: Human Rat (positive ... rat B28 cell lysates and rat ...
... The OneSTrEP Protein Interaction Kit ... single step method to isolate intact ... require tedious optimization or multiple purification ... the highly selective StrepTactin Superflow Column ...
Biology Products: